Presented by Ida Sim, Mobile Health 2011, May 5, 2011

1. !"#$%&'%()*+,#&-./(0,12#'*3#4&5(64+
71%&(8+'9#3%'3:+%
0$*(;#,<(=><(?9>
>#+%'34+<(@%&3%+(64+(@2#&#'*2(*&$(A+*&52*3#4&*2(0&64+,*3#'5
B&#"%+5#3C(46(@*2#64+&#*(;*&()+*&'#5'4
=*C(D<(EF..
.G#39(39*&H5(34(I#'9(J+*"#3K(=><(B@(>*"#5(*&$(L*#9:*(>:*&<(@42:,M#*

2. I%19+*5#&-(N>4%5(#3(G4+HOP
(Complexes of)
Outcome
Exposures strength of association? Increased
Text4Baby individual breastfeeding
population

3. @:++%&3(811+4*'9%5/(I@A
Asthma App ER visits at 1 year
50 people
100 people
Usual Care ER visits at 1 year
50 people population
Q A%535(1+%51%'#R%$(#&3%+"%&3#4&5(*&$(4:3'4,%5
Q A4('4&R+,(*(9C1439%5#5(*3(39%(141:2*3#4&(2%"%2
Q ;3+4&-(#&3%+&*2("*2#$#3C
Q ?+4M2%,5/(524S(34(5%3T:1<(%U1%&5#"%<(594+3T3%+,<(2*'H
+%2%"*&'%(34(39%(+%*2(S4+2$

4. @:++%&3(811+4*'9%5/(>*3*(=#&#&-
EHR
Exposures Outcomes
?
Apps
population
Q !U145:+%5(*&$(4:3'4,%5(6+4,('*+%(1+4'%55(5C53%,5
Q A4(-%&%+*3%(9C1439%5%5(*3(39%(141:2*3#4&(2%"%2
Q ?+4M2%,5/(2#,#3%$(34($*3*('422%'3%$<(S%*H(#&3%+&*2
"*2#$#3C(V$*3*(&43('4,12%3%(4+(5C53%,*3#'W

5. @:++%&3(811+4*'9%5/
LT46T.(;3:$#%5
Asthma app Usual Care Asthma app
peak flow peak flow
Usual Care Asthma app Usual Care
individual
Q G#39#&T5:MX%'3(,:23#12%('+4554"%+
Q 7&2C(64+,*2(,%394$(64+($%3%+,#&#&-(#&$#"#$:*2
3+%*3,%&3(%Y%'3#"%&%55
Q ?+4M2%,5/('4,12#'*3%$(34(5%3(:1<(*&*2C5#5(#5
$#Z':23<(2#332%(H&4S&<(&43(S#$%2C(:5%$

6. !"#$%&'%(!U3+*'3#4&
Q !"#$%&'%(#5(54,%39#&-(34(M%(%U3+*'3%$
6+4,(39%('*+%(1+4'%55
[ ,#&#&-(#3(6+4,(39%($*3*
[ $#+%'32C(,*&#1:2*3#&-(39%('*+%(1+4'%55(S#39
+#-#$(*&$(1+%T$%R&%$(1+434'425

7. !"#$%&'%(;3+#1(=#&#&-

8. !"#$%&'%()*+,#&-
Hay, et al. J Eval Clin Prac 14(2008):707-713.

9. I443#&-(64+(!"#$%&'%

10. 0&$:53+#*2(!"#$%&'%()*+,#&-
Asthma App ER visits at 1 year
50 people
100 people
Usual Care ER visits at 1 year
50 people population

11. ?%+54&*2(!"#$%&'%(*+$%&5
Asthma app Usual Care Asthma app
peak flow peak flow
Usual Care Asthma app Usual Care
individual

12. ?%+54&*2(!"#$%&'%(*+$%&5
Flovent Flovent PRN Flovent
dancing dancing
Flovent PRN Flovent Flovent PRN
individual

13. @+4S$54:+'#&-(G9*3(=*33%+5
Q V@4,12%U%5(46W(!U145:+%5
[ $4%5('94'42*3%(3+#--%+(V,CW(*539,*O
[ 3%53#&-('4,,4&(+%-#,%&5(V8@!0<(53*3#&<(MTM24'H%+W<
'4,12%,%&3*+C(,%$#'#&%5
Q V@4,12%U%5(46W(7:3'4,%5
[ S9*3(4:3'4,%5($4(1*3#%&35('*+%(*M4:3O

14. !"#$%&'%(=*'+45C53%,
Rooting for Industrial Evidence Personal Evidence
Evidence Farming Gardens

15. ]4S('*&(S%(5'*2%(%"*2:*3#4&O

16. ;34"%1#1%$
,]%*239
Q ]%*239(*115(M:#23
#&$%1%&$%&32C
[ 2#332%($*3*(59*+#&-(*&$
#&3%+41%+*M#2#3C
Q ^#,#35(%Z'#%&'C(*&$
#,1*'3(46(_:*2#3C
,]%*239

17. 0&3%+&%3(]4:+-2*55(=4$%2
Q ;3*&$*+$#K%(*&$
,*H%(41%&(39%
N&*++4S(S*#53P
Q I%$:'%5($:12#'*3#4&<
51:+5('4,,:&#3C
#&&4"*3#4&<(5:114+35
'4,,%+'#*2(*&$(&4&T
1+4R3(:5%5

18. 71%&,]%*239`4+-
Estrin DE, Sim I. Science; 330: 759-60. 2010.

19. 71%&,]%*239`4+-
Q A9%(S*#53(594:2$(5:114+3
39%(%"#$%&'%(,*'+45C53%,

20. 71%&(8+'9#3%'3:+%(64+(*&
!"#$%&'%(=*'+45C53%,
Q =4$:2%5(64+(:5*-%(*&*2C3#'5
[ a(46(3%U3(,%55*-%5<(a(46(5%55#4&5<(%3'`
Q I443#&-(64+(V-24'*2W(%"#$%&'%
[ $*3*(59*+#&-(S#39(59*+%$(5C&3*U(*&$(5%,*&3#'5
Q 0&$:53+#*2(6*+,#&-<(%`-`<(S#39(I@A5
[ ,4$:2%5(64+(#&64+,%$('4&5%&3<(+*&$4,#K*3#4&<(*$*13#"%
3+%*3,%&3(53+*3%-C<(,#U%$(,%394$5<(%3'`
Q ?%+54&*2(%"#$%&'%(-*+$%&#&-<(%`-`<(LT46T.
[ ,4$:2%5(64+(5'+#13#&-(*&$(*&*2CK#&-(#&$#"#$:*2#K%$(LT46T
.(1+434'425<(%3'`

21. 71%&(8+'9#3%'3:+%(64+(*&
!"#$%&'%(=*'+45C53%,
Q ;4'#*2(,%$#*(64+($#5'4"%+C(46(%U145:+%5(*&$
4:3'4,%5(39*3(,*33%+
Q ;9*+%$(2#M+*+#%5(46("*2#$*3%$(,%*5:+%5(*&$
#&53+:,%&35(V%`-`<(?I7=0;W
[ ,%*5:+%5(39*3(-%3(*3(R&%+T-+*#&%$(,%'9*&#5,5(M*5%$
4&(39%4+%3#'*2(,4$%25(46('9*&-%<(%3'`

23. 4*2(64+(,]%*239(!"#$%&'%
Q 8(2%*+&#&-('4,,:&#3C('4:12%$(S#39(*&
41%&(*+'9#3%'3:+%(64+(M+4*$<(+*1#$<(*&$
#3%+*3#"%($#55%,#&*3#4&(46(%"*2:*3#4&
,%394$5(*&$(R&$#&-5(39*3(,*33%+

24. Q 0$*(;#,(#$*`5#,b:'56`%$:
Q >%M4+*9(!53+#&($%53+#&b'5`:'2*`%$:
Q 9331/cc41%&,9%*239`4+-c